other material
confidence high
sentiment positive
materiality 0.80
Intellia Phase 2 NTLA-2002: 8/11 patients attack-free after single dose; 77% attack reduction vs placebo
Intellia Therapeutics, Inc.
- Mean monthly attack rate reduced by 77% (50 mg) vs placebo during weeks 1-16; 81% during weeks 5-16.
- Eight of 11 patients in 50 mg arm had zero attacks over 16 weeks and remained attack-free through median 8-month follow-up.
- Kallikrein protein reduction: 86% mean reduction from baseline at week 16 (50 mg) vs 55% (25 mg).
- Well-tolerated; no serious AEs in NTLA-2002 arms; most common AEs were headache, fatigue, nasopharyngitis.
- 50 mg dose selected for global Phase 3 HAELO study, which is actively screening patients.